Shareholder Bvf INC Increased Immune Design Corp (IMDZ) Stake

June 27, 2018 - By Kevin Carney

During Q1 2018 the big money sentiment decreased to 1.57. That’s change of 0.35, from 2017Q4’s 1.92. 11 investors sold all, 12 reduced holdings as IMDZ ratio is negative. 26 grew holdings while 10 funds took holdings. Funds hold 21.61 million shares thus 6.41% less from 2017Q4’s 23.09 million shares. Alliancebernstein Limited Partnership holds 0% of its capital in Immune Design Corp. (NASDAQ:IMDZ) for 11,800 shs. Millennium Mgmt Ltd Company holds 18,301 shs or 0% of its capital. Citigroup owns 5,253 shs for 0% of their capital. Credit Suisse Ag stated it has 12,152 shs or 0% of all its holdings. State Common Retirement Fund holds 0% or 20,100 shs. Goldman Sachs Group Inc, a New York-based fund reported 18,722 shs. California-based Wells Fargo Comm Mn has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Drw Securities Ltd Company invested 0.01% of its capital in Immune Design Corp. (NASDAQ:IMDZ). Ameritas Inv Ptnrs Incorporated reported 874 shs. Bridgeway Management Inc reported 170,000 shs. Barclays Public Ltd Company stated it has 0% in Immune Design Corp. (NASDAQ:IMDZ). Royal Savings Bank Of Canada holds 3,233 shs or 0% of its capital. Voya Inv Mngmt Ltd Liability Corp invested in 13,415 shs. Northern Trust Corp, a Illinois-based fund reported 322,441 shs. The Massachusetts-based Fmr Ltd Liability has invested 0% in Immune Design Corp. (NASDAQ:IMDZ).

IMDZ registered $66,512 net activity with 0 insider purchases and 5 sales since January 4, 2018. Gombotz Wayne sold $8,282 worth of stock. 1,986 shs valued at $8,282 were sold by ter Meulen Jan Henrik on Thursday, January 4. 3,328 shs were sold by Brady Stephen R, worth $13,885 on Thursday, January 4. The insider Paya Carlos V sold $33,247.

Bvf Inc upped its stake by 179.37% in Immune Design Corp (IMDZ), according to 2018Q1 Securities and Exchange filling. The company’s stock rose 30.77% while stock markets declined as Bvf Inc bought 2.64 million shares. At the end of 2018Q1, the hedge fund held 4.11M shares of the major pharmaceuticals company, priced at $13.55 million, up from 1.47M at the end of the previous reported quarter. $202.13 million is Immune Design Corp’s MC. Ticker’s shares touched $4.2 during the last trading session after 4.55% change.Currently Immune Design Corp. is downtrending after 47.53% change in last June 27, 2017. IMDZ has also 42,118 shares volume. IMDZ underperformed by 60.10% the S&P500.

Bvf Inc decreased its stake in Gtx Inc Del by 497,685 shares to 609,748 shares, valued at $10.82 million in 2018Q1, according to the filing. It operates about $999.89M and $986.48M US Long portfolio. For a total of 5.06 million shares it reduced its holding in Array Biopharma Inc (NASDAQ:ARRY) by 3.62 million shares in the quarter, and has cut its stake in Chemocentryx Inc (NASDAQ:CCXI).

More recent Immune Design Corp. (NASDAQ:IMDZ) news were brought out by Nasdaq.com, Nasdaq.com and Seekingalpha.com. The first one has “Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the …” as a title and was brought out on June 25, 2018. The next is “Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global …” on June 01, 2018. And last was brought out on June 12, 2018, called “Is Immune Design Worth A Second Look?”.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.